TY - JOUR AU - Samsom, Kris G. AU - Bosch, Linda J. W. AU - Schipper, Luuk J. AU - Roepman, Paul AU - de Bruijn, Ewart AU - Hoes, Louisa R. AU - Riethorst, Immy AU - Schoenmaker, Lieke AU - van der Kolk, Lizet E. AU - Retèl, Valesca P. AU - Frederix, Geert W. J. AU - Buffart, Tineke E. AU - van der Hoeven, Jacobus J. M. AU - Voest, Emile E. AU - Cuppen, Edwin AU - Monkhorst, Kim AU - Meijer, Gerrit A. PY - 2020 DA - 2020/11/10 TI - Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE) JO - BMC Medical Genomics SP - 169 VL - 13 IS - 1 AB - ‘Precision oncology’ can ensure the best suitable treatment at the right time by tailoring treatment towards individual patient and comprehensive tumour characteristics. In current molecular pathology, diagnostic tests which are part of the standard of care (SOC) only cover a limited part of the spectrum of genomic changes, and often are performed in an iterative way. This occurs at the expense of valuable patient time, available tissue sample, and interferes with ‘first time right’ treatment decisions. Whole Genome Sequencing (WGS) captures a near complete view of genomic characteristics of a tumour in a single test. Moreover, WGS facilitates faster implementation of new treatment relevant biomarkers. At present, WGS mainly has been applied in study settings, but its performance in a routine diagnostic setting remains to be evaluated. The WIDE study aims to investigate the feasibility and validity of WGS-based diagnostics in clinical practice. SN - 1755-8794 UR - https://doi.org/10.1186/s12920-020-00814-w DO - 10.1186/s12920-020-00814-w ID - Samsom2020 ER -